Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Susanne Dietrich

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
International Journal of Technology Assessment in Health Care|July 22, 2009
Effects of the National Institute for Health and Clinical Excellence's technology appraisals on prescribing and net ingredient costs of drugs in the National Health Service in EnglandEva Susanne Dietrich
Pharmazie in Unserer Zeit|April 5, 2005
[Cost-benefit aspects of taxane therapy]Eva Susanne Dietrich
Journal of Medical Economics|April 1, 2025
Artificial intelligence in key pricing, reimbursement, and market access (PRMA) processes: better, faster, cheaper-can you really pick two?Eva Susanne Dietrich
Fertility and Sterility|January 12, 2010
Effects of the Statutory Health Insurance Modernization Act on the supply and expenditure situation in cases of assisted reproductive technologies in GermanyEva Susanne Dietrich, Wenke Wevers
Clinical Pharmacology and Therapeutics|January 5, 2026
On Selection and Analytical Transparency in the FRAME Framework for RWE EvaluationJörg Tomeczkowski, Eva Susanne Dietrich
German Medical Science : GMS E-Journal|August 21, 2010
Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in GermanyStefan Pscherer, Eva Susanne Dietrich, Franz-Werner Dippel, et al.
Chemotherapy|March 20, 2002
Ceftriaxone versus other cephalosporins for perioperative antibiotic prophylaxis: a meta-analysis of 43 randomized controlled trialsEva Susanne Dietrich, Ute Bieser, Uwe Frank, et al.
BMC Health Services Research|May 13, 2023
How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?Michael Drummond, Oriana Ciani, Giulia Fornaro, et al.
Advances in Therapy|June 20, 2025
Letter to the Editor Regarding "Indirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021-2023"Jörg Tomeczkowski, Friedhelm Leverkus, Paul Bussilliat, et al.
Clinical Pharmacology and Therapeutics|May 9, 2024
Questioning Conclusions and Statements on the German HTA System: A Critical PerspectiveJörg Tomeczkowski, Tanja Heidbrede, Friedhelm Leverkus, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
International Journal of Technology Assessment in Health Care|July 22, 2009
Effects of the National Institute for Health and Clinical Excellence's technology appraisals on prescribing and net ingredient costs of drugs in the National Health Service in EnglandEva Susanne Dietrich
Pharmazie in Unserer Zeit|April 5, 2005
[Cost-benefit aspects of taxane therapy]Eva Susanne Dietrich
Journal of Medical Economics|April 1, 2025
Artificial intelligence in key pricing, reimbursement, and market access (PRMA) processes: better, faster, cheaper-can you really pick two?Eva Susanne Dietrich
Fertility and Sterility|January 12, 2010
Effects of the Statutory Health Insurance Modernization Act on the supply and expenditure situation in cases of assisted reproductive technologies in GermanyEva Susanne Dietrich, Wenke Wevers
Clinical Pharmacology and Therapeutics|January 5, 2026
On Selection and Analytical Transparency in the FRAME Framework for RWE EvaluationJörg Tomeczkowski, Eva Susanne Dietrich
German Medical Science : GMS E-Journal|August 21, 2010
Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in GermanyStefan Pscherer, Eva Susanne Dietrich, Franz-Werner Dippel, et al.
Chemotherapy|March 20, 2002
Ceftriaxone versus other cephalosporins for perioperative antibiotic prophylaxis: a meta-analysis of 43 randomized controlled trialsEva Susanne Dietrich, Ute Bieser, Uwe Frank, et al.
BMC Health Services Research|May 13, 2023
How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?Michael Drummond, Oriana Ciani, Giulia Fornaro, et al.
Advances in Therapy|June 20, 2025
Letter to the Editor Regarding "Indirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021-2023"Jörg Tomeczkowski, Friedhelm Leverkus, Paul Bussilliat, et al.
Clinical Pharmacology and Therapeutics|May 9, 2024
Questioning Conclusions and Statements on the German HTA System: A Critical PerspectiveJörg Tomeczkowski, Tanja Heidbrede, Friedhelm Leverkus, et al.
Pageof 1